- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SCIBASE Aktie jetzt für 0€ handeln | |||||
| 01.08. | SciBase announces outcome in directed share issue | 265 | PR Newswire | STOCKHOLM, Aug. 1, 2025 /PRNewswire/ -- On 16 June 2025, SciBase Holding AB (publ) ("SciBase" or the "Company") announced that the Company's Board of Directors resolved, pursuant to the authorisation... ► Artikel lesen | |
| 09.07. | SciBase Launches Nevisense Pilot at Leading University in Southeast Florida | 209 | PR Newswire | STOCKHOLM, July 9, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that a... ► Artikel lesen | |
| 07.07. | SciBase: A new important customer in the US, Palm Beach Dermatology Group, has placed an initial order for 6 Nevisense. | 258 | PR Newswire | STOCKHOLM, July 7, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, is pleased to announce... ► Artikel lesen | |
| 30.06. | SciBase announces outcome in directed share issue | 159 | PR Newswire | STOCKHOLM, June 30, 2025 /PRNewswire/ -- On 23 June 2025, SciBase Holding AB (publ) ("SciBase" or the "Company") announced that the Company's board of directors resolved, pursuant to the... ► Artikel lesen | |
| 23.06. | SciBase resolves on a directed share issue of approximately SEK 11 million | 295 | PR Newswire | STOCKHOLM, June 23, 2025 /PRNewswire/ -- The board of directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, in accordance with the intention published by the Company... ► Artikel lesen | |
| 17.06. | Bulletin from the annual general meeting in SciBase Holding AB (publ) | 398 | PR Newswire | STOCKHOLM, June 17, 2025 /PRNewswire/ -- Today, the annual general meeting 2025 has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved in accordance... ► Artikel lesen | |
| 17.06. | SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30 | 341 | PR Newswire | STOCKHOLM, June 17, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced it has signed... ► Artikel lesen | |
| 16.06. | Castle Biosciences partners with SciBase for diagnostic tests | 1 | Seeking Alpha | ||
| 16.06. | SciBase resolves on a directed share issue of SEK 19 million and announces its intention to carry out an additional directed share issue of approximately SEK 11 million | 384 | PR Newswire | STOCKHOLM, June 16, 2025 /PRNewswire/ -- The board of directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, pursuant to the authorisation granted by the annual general... ► Artikel lesen | |
| 16.06. | Castle Biosciences partners with SciBase to develop atopic dermatitis test | 1 | Investing.com | ||
| 16.06. | Castle Biosciences, Inc.: Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases | 150 | GlobeNewswire (Europe) | FRIENDSWOOD, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it... ► Artikel lesen | |
| 09.06. | SciBase Initiates Self-Pay Model in the US to Make Nevisense Test More Accessible to Patients | 288 | PR Newswire | STOCKHOLM, June 9, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, today announced the launch... ► Artikel lesen | |
| 04.06. | SciBase Expands Further Through European Market with First Sales Order to customer in Italy | 235 | PR Newswire | STOCKHOLM, June 4, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, today announced its first... ► Artikel lesen | |
| 27.05. | SciBase reaches milestone with over 300,000 patients tested with Nevisense | 241 | PR Newswire | STOCKHOLM, May 27, 2025 /PRNewswire/ -- SciBase Holding AB ('SciBase') (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, today announced a major... ► Artikel lesen | |
| 23.05. | SciBase publishes the Annual report for 2024 | 264 | PR Newswire | STOCKHOLM, May 23, 2025 /PRNewswire/ -- SciBase hereby announces that the Annual report for 2024 is available at the Company's website www.scibase.com.
A pdf-version of the annual report... ► Artikel lesen | |
| 14.05. | Notice to attend the annual general meeting in Scibase Holding AB (publ) | 271 | PR Newswire | STOCKHOLM, May 14, 2025 /PRNewswire/ -- Shareholders of SciBase Holding AB (publ), reg. no. 556773-4768 (the "Company"), are hereby summoned to the annual general meeting to be held on 17... ► Artikel lesen | |
| 13.05. | SciBase: Interim report | 259 | PR Newswire | STOCKHOLM, May 13, 2025 /PRNewswire/ --
January 1 - March 31, 2025
The first quarter in figures
Net sales were TSEK 8,856 (6,057), +46%. The loss after tax was TSEK 27,510... ► Artikel lesen | |
| 11.04. | SciBase launches next generation Nevisense | 286 | PR Newswire | STOCKHOLM, April 11, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, is proud to announce... ► Artikel lesen | |
| 25.02. | Year-end report: SciBase | 318 | PR Newswire | STOCKHOLM, Feb. 25, 2025 /PRNewswire/ --
January 1 - December 30, 2024
The fourth quarter in figures
Net sales were TSEK 8,598 (5,764), +49%.The loss after tax was TSEK 17... ► Artikel lesen | |
| 25.02. | SCIBASE: Year-end report | 5 | Cision News |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ROKU | 77,70 | +3,39 % | Jefferies reiterates Hold rating on Roku stock, cites AI momentum | ||
| SERNOVA BIOTHERAPEUTICS | 0,118 | -0,84 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes | LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics ("Sernova") (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals... ► Artikel lesen | |
| BOSTON SCIENTIFIC | 88,00 | -1,79 % | Consumer alert: Recall notice issued for certain Boston Scientific Encore medical devices and kits | ||
| PAUL HARTMANN | 231,00 | +0,43 % | Januar bis Juni 2025: PAUL HARTMANN behauptet sich in herausforderndem Marktumfeld | Heidenheim (ots) - - Umsatzerlöse steigen auf 1.214,0 Mio. EUR, organisches Umsatzwachstum von 1,6 % - Bereinigtes EBITDA liegt bei 125,8 Mio. EUR, bereinigte EBITDA-Rendite bei 10,4 % - Transformationsprogramm... ► Artikel lesen | |
| SYSMEX | 11,800 | +0,85 % | Sysmex Q1 Profit Declines | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Sysmex reported first quarter profit attributable to owners of the parent of 4.55 billion yen, down 58.7% from last year. Earnings per share was 7.30 yen... ► Artikel lesen | |
| ADDLIFE | 14,730 | +0,07 % | AddLife AB: Interim Report January 1 - June 30, 2025 | Continued improvement in margins and profit"The companies within AddLife continue to develop in line with our priorities. Margins are strengthening in both business areas thanks to continuous development... ► Artikel lesen | |
| EMBECTA | 11,900 | -0,83 % | Embecta Corp. Reports Third Quarter Fiscal 2025 Financial Results | PARSIPPANY, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and nine... ► Artikel lesen | |
| ENOVIS | 26,000 | +4,84 % | Enovis raises 2025 revenue guidance to $2.275B amid CEO transition and product momentum | ||
| KANGJI MEDICAL | 0,910 | 0,00 % | XFRA 50J: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| PULMONX | 1,300 | 0,00 % | Pulmonx korrigiert Umsatzprognose nach unten - US-Geschäft schwächelt | ||
| REVITALIST LIFESTYLE AND WELLNESS | 0,015 | -100,00 % | Revitalist Lifestyle & Wellness Ltd: Revitalist Announces Filing of Audited Financial Statements for the Year-Ended December 31, 2022 and Provides Update on Cease Trade Order | Vancouver, British Columbia--(Newsfile Corp. - February 18, 2025) - Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) (the "Company") wishes to announce that, further to... ► Artikel lesen | |
| SI-BONE | 13,500 | +2,27 % | SI-BONE stock price target reiterated at $25 by Cantor Fitzgerald | ||
| KOOTH | 1,800 | 0,00 % | Kooth PLC - Appointment of Joint Corporate Broker | ||
| PEIJIA MEDICAL | 0,965 | +4,32 % | PEIJIA-B (09996): DATE OF BOARD MEETING | ||
| LIFECARE ASA | 1,275 | -18,01 % | Lifecare ASA: Lifecare advances CE mark preparation for its groundbreaking medical device |
Das Unternehmen SCIBASE HOLDING AB kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,010 Euro und damit +15,91 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SCIBASE HOLDING AB finden Sie auf Wallstreet Online.